Phase 3 Clinical Trials With Primary Completion Dates in December 2022

This is a list of Phase 3 trials with primary completion dates in December 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AKBA Akebia Therapeutics, Inc. 2022-12-01 Phase 3 NCT04707768 Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
AMRX Amneal Pharmaceuticals, Inc. 2022-12-01 Phase 3 NCT05401357 Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
ARQT Arcutis Biotherapeutics, Inc. 2022-12-01 Phase 3 NCT04845620 Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
AXSM Axsome Therapeutics, Inc. 2022-12-01 Phase 3 NCT04797715 Assessing Clinical Outcomes in Alzheimer's Disease Agitation
BIVI BioVie Inc. 2022-12-01 Phase 3 NCT04669028 A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
BVNRY Bavarian Nordic A/S 2022-12-01 Phase 3 NCT05329220 ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
CORT Corcept Therapeutics Incorporated 2022-12-01 Phase 3 NCT04308590 Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
EIGR Eiger BioPharmaceuticals, Inc. 2022-12-01 Phase 3 NCT03719313 Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
ESPR Esperion Therapeutics, Inc. 2022-12-01 Phase 3 NCT02993406 Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
IMGN ImmunoGen, Inc. 2022-12-01 Phase 3 NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
ITCI Intra-Cellular Therapies, Inc. 2022-12-01 Phase 3 NCT04285515 Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
IVBXF Innovent Biologics, Inc. 2022-12-01 Phase 3 NCT04277663 The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
IVBXF Innovent Biologics, Inc. 2022-12-01 Phase 3 NCT03607539 Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
IVBXF Innovent Biologics, Inc. 2022-12-01 Phase 3 NCT03150875 A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
MDGL Madrigal Pharmaceuticals, Inc. 2022-12-01 Phase 3 NCT03900429 A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
MEDP Medpace Holdings, Inc. 2022-12-01 Phase 3 NCT03464019 Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)]
MIST Milestone Pharmaceuticals Inc. 2022-12-01 Phase 3 NCT04072835 Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
MIST Milestone Pharmaceuticals Inc. 2022-12-01 Phase 3 NCT03464019 Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)]
MMSI Merit Medical Systems, Inc. 2022-12-01 Phase 3 NCT03960008 Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
NAMS NewAmsterdam Pharma Company N.V. 2022-12-01 Phase 3 NCT05142722 Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
NEPH Nephros, Inc. 2022-12-01 Phase 3 NCT04466618 Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes
NEPH Nephros, Inc. 2022-12-01 Phase 3 NCT04459338 A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion
OPTN OptiNose, Inc. 2022-12-01 Phase 3 NCT03747458 OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
OTLK Outlook Therapeutics, Inc. 2022-12-01 Phase 3 NCT05112861 A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
RLMD Relmada Therapeutics, Inc. 2022-12-01 Phase 3 NCT04855747 A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
SPPI Spectrum Pharmaceuticals, Inc. 2022-12-01 Phase 3 NCT01478542 OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
STSA Satsuma Pharmaceuticals, Inc. 2022-12-01 Phase 3 NCT04406649 A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
URGN UroGen Pharma Ltd. 2022-12-01 Phase 3 NCT05136898 Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)
VBLT Vascular Biogenics Ltd. 2022-12-01 Phase 3 NCT03398655 A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
VNDA Vanda Pharmaceuticals Inc. 2022-12-01 Phase 3 NCT04652882 Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
ZLDPF Zealand Pharma A/S 2022-12-01 Phase 3 NCT04991311 The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
ZLDPF Zealand Pharma A/S 2022-12-01 Phase 3 NCT03941236 Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism